UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer (vol 21, pg 696, 2016)

Miyata Yoshinori; Touyama Tetsuo; Kusumi Takaya; Morita Yoshitaka; Mizunuma Nobuyuki; Taniguchi Fumihiro; Manabe Mitsuaki

首页> 外文期刊>International journal of clinical oncology >UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer (vol 21, pg 696, 2016)

【24h】

UDP-glucuronosyltransferase 1A16 and 28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer (vol 21, pg 696, 2016)

机译：UDP-葡萄糖醛酸转移酶1A1 * 6和* 28多态性可作为伊立替康初始剂量水平的指标，以降低接受FOLFIRI治疗的大肠癌患者中性粒细胞减少的风险（第21卷，第696页，2016年）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《International journal of clinical oncology》 |2016年第4期|共1页
作者
Miyata Yoshinori; Touyama Tetsuo; Kusumi Takaya; Morita Yoshitaka; Mizunuma Nobuyuki; Taniguchi Fumihiro; Manabe Mitsuaki;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer (vol 21, pg 696, 2016) [J] . Miyata Yoshinori, Touyama Tetsuo, Kusumi Takaya, International journal of clinical oncology . 2016,第4期

机译：UDP-葡萄糖醛酸转移酶1A1 * 6和* 28多态性可作为伊立替康初始剂量水平的指标，以降低接受FOLFIRI治疗的大肠癌患者中性粒细胞减少的风险（第21卷，第696页，2016年）
2. A Phase I Study of UGT1A1*28/*6 Genotype-Directed Dosing of Irinotecan (CPT-11) in Korean Patients with Metastatic Colorectal Cancer Receiving FOLFIRI [J] . Kim Kyu-Pyo, Hong Yong Sang, Lee Jae-Lyun, Oncology: International Journal of Cancer Research and Treatment . 2015,第3期

机译：在韩国接受FOLFIRI的转移性结直肠癌患者中，UGT1A1 * 28 / * 6基因型定向伊立替康剂量（CPT-11）的I期研究
3. UDP-glucuronosyltransferase (UGT) 1A1*28 polymorphismdirected phase ii study of irinotecan with 5'-deoxy-5- fluorouridine (5'-DFUR) for metastatic colorectal cancer [J] . KanekiyoS., HazamaS., KondoH., Anticancer Research: International Journal of Cancer Research and Treatment . 2013,第8期

机译：UDP-葡糖醛酸糖基转移酶（UGT）1A1 * 28多态性研究伊立替康与5'-脱氧-5-氟尿苷（5'-DFUR）用于转移性结直肠癌的II期研究
4. UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer [O] . Yoshinori Miyata, Tetsuo Touyama, Takaya Kusumi, -1

机译：UDP-葡萄糖醛酸转移酶1A1 * 6和* 28多态性可作为伊立替康初始剂量水平的指标以降低接受FOLFIRI治疗的大肠癌患者中性粒细胞减少症的风险
5. and polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer [O] . 2016

机译：和多态性可作为伊立替康初始剂量水平的指标，以降低接受FOLFIRI治疗的大肠癌患者中性粒细胞减少的风险

UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer (vol 21, pg 696, 2016)

著录项

相似文献

相关主题

期刊订阅

UDP-glucuronosyltransferase 1A16 and 28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer (vol 21, pg 696, 2016)